Marilyn Enderson
Administrative Manager at BiPar Sciences - South San Francisco, California, United States
Marilyn Enderson's Colleagues at BiPar Sciences
Marilyn Enderson's Contact Details
BiPar Sciences
Marilyn Enderson's Company Details
BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors, designed to target multiple cancer types, including therapy-resistant and difficult-to-treat cancers. BiPar Sciences' lead product candidate, iniparib, the United States Adopted Name (USAN) for the investigational PARP1 inhibitor, BSI-201, targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and cell proliferation. Iniparib significantly enhances the anti-tumor effects of chemotherapy and has shown promising safety and efficacy results in patients with solid tumors.Iniparib is being evaluated in multiple Phase 2 and Phase 3 clinical trials in advanced solid tumors, including triple-negative breast cancer. The company also has two additional compounds in pre-clinical development: BSI-401, a follow-on PARP inhibitor candidate being investigated as an oral therapy for pancreatic cancer, and BSI-302, a novel anti-tubulin therapy